open access

Vol 9, No 3 (2004)
Review paper
Published online: 2004-01-01
Submitted: 2003-12-11
Get Citation

Continuing Maciejewski's debate on radiotherapy for locally advanced prostate cancer: I have even more dilemmas

Rafał Suwiński
DOI: 10.1016/S1507-1367(04)71014-7
·
Rep Pract Oncol Radiother 2004;9(3):81-88.

open access

Vol 9, No 3 (2004)
Review paper
Published online: 2004-01-01
Submitted: 2003-12-11

Abstract

A recent critical review of clinical trials on radiotherapy for locally advanced prostate cancer by Maciejewski et al. [1] points to a conclusion that most of conventional 5-days-a-week, 2 Gy fraction regimes produce a “plateau effect”. Thus an increase in the total dose above approximately 70 Gy would not improve local tumour control, but could elevate the risk of later complications. Maciejewski et al. propose that radical hypofractionated 3D conformal or dose-intensity modulated radiotherapy with or without 3D HDR boost dose painting may improve the outcome of prostate radiotherapy. The present response describes some unforeseen challenges which may appear while implementing these new treatment strategies in clinical practice, and suggests possible solutions to solve these problems. Also, an alternative viewpoint on the data on dose-response in radiotherapy for prostate cancer is presented. It is postulated that, in addition to tumour hypoxia, distant metastases may create a quasi-plateau in dose-response, when biochemical failures and not loco-regional tumour control are used as the endpoint. Some arguments for the presence of dose response in postoperative EBRT for prostate cancer are presented. This some-what contradictory review of the existing data on radiotherapy for prostate cancer may be considered as a stimulus for further discussion regarding optimization of local therapy. It also illustrates an urgent need for new prospective trials, which would address the clinical and radiobiological ambiguities of theoretical predictions.

Abstract

A recent critical review of clinical trials on radiotherapy for locally advanced prostate cancer by Maciejewski et al. [1] points to a conclusion that most of conventional 5-days-a-week, 2 Gy fraction regimes produce a “plateau effect”. Thus an increase in the total dose above approximately 70 Gy would not improve local tumour control, but could elevate the risk of later complications. Maciejewski et al. propose that radical hypofractionated 3D conformal or dose-intensity modulated radiotherapy with or without 3D HDR boost dose painting may improve the outcome of prostate radiotherapy. The present response describes some unforeseen challenges which may appear while implementing these new treatment strategies in clinical practice, and suggests possible solutions to solve these problems. Also, an alternative viewpoint on the data on dose-response in radiotherapy for prostate cancer is presented. It is postulated that, in addition to tumour hypoxia, distant metastases may create a quasi-plateau in dose-response, when biochemical failures and not loco-regional tumour control are used as the endpoint. Some arguments for the presence of dose response in postoperative EBRT for prostate cancer are presented. This some-what contradictory review of the existing data on radiotherapy for prostate cancer may be considered as a stimulus for further discussion regarding optimization of local therapy. It also illustrates an urgent need for new prospective trials, which would address the clinical and radiobiological ambiguities of theoretical predictions.

Get Citation

Keywords

Dose response; Relationship; Therapeutic controversies; Prostate cancer

About this article
Title

Continuing Maciejewski's debate on radiotherapy for locally advanced prostate cancer: I have even more dilemmas

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 3 (2004)

Pages

81-88

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71014-7

Bibliographic record

Rep Pract Oncol Radiother 2004;9(3):81-88.

Keywords

Dose response
Relationship
Therapeutic controversies
Prostate cancer

Authors

Rafał Suwiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl